Heart failure & cardiomyopathies
Cardiac Resynchronization Therapy and Circulating Metabolomic Profile in Patients With Advanced Heart Failure
Authors' conclusion
CRT may modulate the systemic plasma metabolomic profile, which correlated with improvement in left ventricular function in patients with severe heart failure with reduced ejection fraction.
Study context
- Population
- Patients with ischemic cardiomyopathy and nonischemic cardiomyopathy who received cardiac resynchronization therapy (CRT) with a defibrillator for left ventricular ejection fraction (LVEF) ≤35%patients enrolled
- Participants
- 92 patients
- Exposure
- Before CRT vs 6-month follow-up
Methodological detailsprospectively screened
- Prospectively screened
Main finding
As reported in the abstract
LVEF · 6 and 12 months
Baseline
28.9±7.6%
6 months
36.0±11.3%
P <0.001
12 months
40.1±12.6%
P <0.001
Observational data: associations, not effects.
Further findings
Metabolite features after CRT
- Metabolite features significantly decreased compared with the baseline
- 42
- 3-hydroxybutyrate reduced
- P < 0.001
- Acetone reduced
- P = 0.01
- Isoleucine decreased after CRT
- P = 0.01
Metabolomic changes by cardiomyopathy type
- Changes mainly observed in the nonischemic cardiomyopathy group
- Ischemic cardiomyopathy group: enhanced amino acid oxidation and elevated levels of lactate and pyruvate
Correlation of LVEF improvement with metabolite changes
- Improvement in LVEF positively correlated with the ratio of changes in ketone bodies and isoleucine
Original publication
Cardiac Resynchronization Therapy and Circulating Metabolomic Profile in Patients With Advanced Heart Failure. Circ Heart Fail. Published 10 September 2026. doi:10.
Summarised from the published abstract; every number is checked against it